Common medical screen predicts liver cancer risk in general population
MD Anderson News Release October 16, 2012
Enzymes checked in routine blood tests gauge risk better than hepatitis infection, other factors
MD Anderson News Release 10/16/12
Enzyme levels in the blood routinely monitored by physicians as liver function indicators are also the best predictor of liver cancer risk in the general population, a team of scientists in Taiwan and The University of Texas MD Anderson Cancer Center reports today in the Journal of the National Cancer Institute.
"These two enzymes alone predicted 91 percent of liver cancer cases in our prospective study," said senior author Xifeng Wu, M.D., Ph.D., professor and chair of MD Anderson's Department of Epidemiology. "If our research is confirmed in other studies, we'd have a measure for liver cancer risk that's easy to apply via a simple blood test that's already in widespread clinical use."
While hepatitis B and hepatitis C virus infection are predictors of cancer risk among people considered at high risk of developing liver cancer, the enzyme levels outperformed both HBV and HCV infection as risk predictors in a general population. Between 30 and 40 percent of people who develop liver cancer are not infected with either virus. There has been no way to assess their risk, Wu noted.
"Knowing their risk would allow people to respond with lifestyle changes to address other risk factors, such as stopping smoking, reducing alcohol consumption, engaging in physical activity and better managing diabetes," Wu said.
According to the National Cancer Institute, 5-year survival rates for liver cancer patients range from:
- 27.7 percent of those with disease limited to the liver upon diagnosis;
- 10 percent of those whose disease has spread to lymph nodes; and
- only 2.1 percent of those with disease that has spread to other organs.
Triumph of transaminases
Wu and colleagues' prospective study evaluated comprehensive medical, demographic and lifestyle data from 428,584 people in Taiwan from 1994 to 2008 who are covered by MJ Health Management, the largest private health-screening company in Asia. Average follow-up was 8.5 years.
The researchers divided study participants into two groups: the 130,533 who had known HCV test results and the other 298,051. They found 1,668 cases of liver cancer.
Wu and colleagues then analyzed data routinely gathered by MJ Health Management based on screening for 100 separate factors and a 100-item questionnaire. Information included:
- Personal characteristics such as age, gender, height, weight, body fat percentage, blood pressure, pulse rate and respiration rate.
- Medical history including stroke, high blood pressure, heart disease and diabetes.
- Blood tests after overnight fasting to check blood counts, blood sugar, liver, kidney and thyroid function, lipid levels, and HBV or HCV infection.
- Lifestyle factors such as alcohol consumption, smoking and physical activity.
The researchers developed their risk prediction models by dividing each cohort in half, which allowed them to base the model on one set and then validate the model in the second set. They applied a stepwise regression analysis to identify risk predictors that were statistically significant when multiple variables are taken into account.
Five models were analyzed: health history alone, transaminase enzymes alone, health history plus transaminases, and a model that added HBV status and AFP protein level to the third model. The fifth model added HCV, including all five factors. They found:
- The model that relied only on levels of the enzymes alanine transaminase (ALT) and aspartate transaminase (AST) predicted 91.2 percent of cancer cases.
- Both HBV and HCV separately predicted 84 percent of cases.
- Adding HCV and HBV to the transaminase model only boosted predictive power to 93.3 percent.
- All five factors raised prediction to 94 percent.
Elevated levels of the two enzymes, which are involved in producing amino acids, are an indicator of liver damage. The scientists found that levels of ALT or AST at or above 25 international units per liter of blood were predictive of cancer risk. This is less than the 40IU/L commonly defined as the upper limit of normal levels.
Their models were applied to eight hypothetical people with varying risk profiles. A person with HBV but with abnormal transaminase had a probability of 38.2 percent of having liver cancer in 10 years. A person with HBV and normal transaminases would have only a .3 percent risk at 10 years if other risk factors are equal to the first person.
"We think our models will apply generally, but validation studies must be conducted in other populations," Wu said.
Future plans include putting the risk models on a website for public use.
According to the National Cancer Institute, an estimated 28,750 new cases of liver cancer will be diagnosed in 2012 and 20,550 people will die from the disease.
Worldwide, an estimated 749,000 cases were diagnosed in 2008, the latest year available, and 695,000 people died, according to the International Agency for Research on Cancer. Countries in Asia, Africa and Southern Europe have the highest incidence of the disease.
Co-authors with Wu are co-first authors Chi-Pang Wen, M.D., of the Institute of Population Science, National Health Research Institutes, Taiwan; and Jie Lin, Ph.D., of MD Anderson's Department of Epidemiology. Also in that department are Carol Etzel, Ph.D., Maosheng Huang and Yuanqing Ye, Ph.D.; Other co-authors with Taiwan's Institute of Population Sciences are Yi Cheng Yang and Min Kuang Tsai; Chwen Keng Tsao and Chung Yi Hsu, M.D., Ph.D., of China Medical University Hospital, Taiwan; Lopa Mishra, M.D. , of MD Anderson's Department of Gastroenterology, Hepatology and Nutrition; and Ernest Hawk, M.D., head of MD Anderson's Division of Cancer Prevention and Population Sciences and vice president, prevention.
The study was funded by grants from the MD Anderson Center for Translational and Public Health Genomics of the Duncan Family Institute for Cancer Prevention and Risk Assessment, MD Anderson Cancer Center Trust, and the Taiwan Department of Health Clinical Trial and Research Center of Excellence.